Background
==========

The presence of endometrial glandular and stromal cells outside the uterine cavity is called endometriosis. Endometriosis is one of the most common benign diseases affecting quality of life and fertility of women. Endometriosis is diagnosed by visual inspection of the pelvis during laparoscopy and positive histology confirms the diagnosis, but negative histology does not exclude it \[[@b1-medscimonit-19-534]\]. Multiple factors are responsible for endometriosis. The most important one is regurgitation of menstrual blood, but cytokines play a critical role in facilitation of the implantation of ectopic endometrial tissues \[[@b2-medscimonit-19-534]\]. Numerous data indicate that eutopic endometrial glandular and stromal cells may be functioning differently in women with endometriosis compared to normal endometrium in disease-free women \[[@b3-medscimonit-19-534]\]. Expression of Importin13, a possible marker for endometrial stem cells, compared to secretory endometrium, might support the hypothesis that this disease originates from stem cells \[[@b4-medscimonit-19-534]\]. The most prominent symptoms of endometriosis are dyspareunia, dysmenorrhea, pelvic pain, and infertility. All endometriosis lesion types are associated with pelvic pain and dysmenorrhea. Current treatment of endometriosis is mainly based on surgery and ovarian suppressive agents. Some medical treatments have been suggested for endometriosis, including oral contraceptive pills, medroxy progesterone acetate, and gonadotropin-releasing hormone agonists (GnRHa) \[[@b1-medscimonit-19-534]\]. In some studies statins were effective in prevention of endometriotic cells proliferation *in vitro*.

Statins are potent inhibitors of cholesterol biosynthesis to reduce serum cholesterol in patients with hyperlipidemia. Statins act by inhibiting 3-Hydroxy-3-Methyl Glutaryl Coenzyme A (HMG-CoA) reductase to block the conversion of HMG-CoA to L-mevalonate, a rate-limiting step in cholesterol synthesis. Statins were effective in inhibiting the mechanisms of cell proliferation and angiogenesis in experimental models for the development of endometriosis-like tissue \[[@b5-medscimonit-19-534]--[@b7-medscimonit-19-534]\]. In 1 study using a nude mouse model, simvastatin induced a dose-dependent decrease of the number and size of endometrial implants in mice. At the highest dose of simvastatin, the number of endometrial implants decreased by 87% and the volume by 98% \[[@b8-medscimonit-19-534]\]. In another study on endometriotic cyst walls and endometrial biopsy *in vitro*, atorvastatin treatment had no effect on 17βE~2~ levels in endometriotic stromal cell culture supernatant, and concluded that atorvastatin can be used as a treatment for endometriosis in humans \[[@b9-medscimonit-19-534]\].

Different studies have suggested that the role of statins in inhibition of aromatase activity may represent a new therapeutic option for endometriosis. After approval by ethics committee of Tehran University of Medical Sciences (TUMS) and after counseling with patients with pelvic endometriosis, we compared the clinical symptoms of patients after prescription of GnRHa with simvastatin.

Material and Methods
====================

This study was conducted as a prospective, randomized, controlled trial to compare the effectiveness of simvastatin with that of GnRHa treatment, after surgery for endometriosis, on pain due to endometriosis. In our gynecology ward, all the patients with the laparoscopic diagnosis of pelvic endometriosis were included in the study. All of the subjects underwent conservative laparoscopic surgery. Laparoscopy was performed under general anesthesia, using the triple puncture technique. In laparoscopy, the surgeons tried to excise or ablate all the endometriotic implants and performed adhesiolysis. The night before laparoscopy, a data collection form was completed by a physician. The cause of laparoscopy and the severity of dyspareunia, dysmenorrhea, and pelvic pain were estimated by use of the Visual Analogue Scale test (VAS test), with a score of 0 being no pain and 10 being the most severe pain ever experienced. After the operation, the severity of endometriosis was entered into the data collection form as revised according to the American Society for Reproductive Medicine classification for endometriosis \[[@b1-medscimonit-19-534],[@b10-medscimonit-19-534]\]. The staging was done intraoperatively by the 2 surgeons who were involved in the operations. Following ethics committee approval and obtaining informed consent in cases of simvastatin prescription, we prescribed simvastatin (film-coated tablet simvaHEXAL, 20 mg daily for 4 months) or GnRHa (Decapeptyl 3.75 mg IM each 28 day period for 4 doses) at the time of discharge. The patients were randomly assigned to either the simvastatin or Decapeptyl group (assigned to each group alternately in order of admission). Although the patient selection was random, in patients who wanted to become pregnant immediately, we had the obligation to prescribe simvastatin rather than GnRHa. None of the patients had a history of previous surgery or GnRHa treatment. We followed the patients for continuation of drugs and adverse effects of simvastatin. Each group had 30 patients and we tried to match the two groups for age, the severity of endometriosis and severity of endometriotic pain. Six months after operation, we reassessed the patients' symptoms by VAS.

We analyzed the data by SPSS 13, using the KS test (one-sample Kolmogorov-Smirnov test) for normality of data distribution, Levene's test for equality of variances, and independent samples t-test for equality of means for comparing quantitative normal data between the 2 groups, paired sample t-tests for comparing quantitative normal data between before and after treatment in each group and Pearson chi-square test for matching and comparing categorical variables between the 2 groups. According to the KS test, we compared the non-normal quantitative data by Mann-Whitney U nonparametric test between the 2 groups and Wilcoxon signed ranks test for comparing before and after treatment data in each group.

Results
=======

In these 60 patients, 40 had endometrioma of ovary; the size of endometrioma was most often 3--10 centimeters (n=37). In this study, marital status of the 2 patient groups -- the simvastatin group (S) and the GnRHa group (G) -- was matched (P=0.793), but the difference for presence of endometrioma between the two groups was significant (P=0.045), ([Table 1](#t1-medscimonit-19-534){ref-type="table"}).

The major reasons for laparoscopy in the simvastatin group were infertility (40.0%) and ovarian cyst (33.3%) and ovarian cyst (40.0%) and dysmenorrhea (30.0%) in the GNRHa group ([Table 2](#t2-medscimonit-19-534){ref-type="table"}).

Severity of endometriosis in the 2 patient groups was not significantly different (P=0.253) ([Table 3](#t3-medscimonit-19-534){ref-type="table"}).

The severity of dyspareunia, dysmenorrhea, and pelvic pain before and after treatment were not significantly different between the 2 groups ([Table 4](#t4-medscimonit-19-534){ref-type="table"}). However, after treatment, the severity of dyspareunia, dysmenorrhea, and pelvic pain in the 2 groups was significantly reduced and the difference between before and after treatment in 3 parameters in each group was significant ([Table 5](#t5-medscimonit-19-534){ref-type="table"}). None of the patients showed adverse effects of simvastatin and all continued medical treatment for 4 months. Three of the patients in the simvastatin group became pregnant 4 months after surgery. All of them had mild endometriosis.

Discussion
==========

The major finding of this prospective, randomized, double-blind trial of simvastatin *versus* Decapeptyl in the treatment of endometriotic pains was that after ablative surgery, prescription of simvastatin or Decapeptyl resulted in no significant difference in outcome.

Endometriosis is a common, often painful, condition, frequently associated with infertility. Endometriosis is found in 33% of infertile women \[[@b1-medscimonit-19-534]\]. Laparoscopy is recognized as the first option for diagnosis and treatment of endometriosis, but the rate of pain recurrence after conservative surgery is high. GnRH agonists have long been used successfully in the treatment of endometriosis \[[@b1-medscimonit-19-534],[@b11-medscimonit-19-534]--[@b15-medscimonit-19-534]\], but because of their adverse effects (loss of bone minerals and vasomotor symptoms), physicians need better choices.

Statins, inhibitors of 3-hydroxy-3methylglutaryl-coenzyme A reductase (HMGCR), have been shown to decrease proliferation of several mesenchymal tissues. Actions of statins may be related to decrease in availability of cholesterol, as well as intermediate metabolites of mevalonate pathway downstream of HMGCR. Statin affects the growth of endometriotic tissues by inhibiting angiogenesis \[[@b8-medscimonit-19-534],[@b16-medscimonit-19-534]\]. This could be important in non-hormonal and non-surgical treatment of endometriosis. The effectiveness of simvastatin in inhibition of endometriotic tissue has been confirmed *in vitro*. Proliferation of endometrial stromal cells has been inhibited with simvastatin in endometrial tissue obtained from 4 women with endometriosis. Therefore, it is suggested that simvastatin could potentially be a therapeutic agent for treatment of endometriosis \[[@b7-medscimonit-19-534]\]. The *in vitro* studies demonstrated that simvastatin induced a concentration-dependent inhibition of human endometrial stromal cell proliferation, evidenced by reduced DNA synthesis and a decrease in number of viable cells \[[@b7-medscimonit-19-534]\]. It has also shown that simvastatin inhibits the proliferation of stromal cells derived from human endometriotic implants in ovaries \[[@b5-medscimonit-19-534]\].

Simvastatin reduced both the number and volume of endometriotic lesions in nude mice in a dose-dependent manner. About 85% of the mice in the control group developed lesions, whereas 58% of the mice receiving low-dose simvastatin and only 17% of those given high-dose simvastatin had lesions. These findings suggested that the use of statins for treatment of endometriosis can be effective \[[@b8-medscimonit-19-534],[@b17-medscimonit-19-534]\].

In our study, after conservative surgical treatment, the result of prescription of simvastatin (20 mg daily for 4 months) was similar to Decapeptyl (3.75 mg IM for 4 doses) in control of endometriotic pain.

Limitations of study
--------------------

Our study has some limitations. The sample size was small and the study must be repeated with larger sample sizes and with other doses of simvastatin. In addition, none of the patients accepted second-look laparoscopy to evaluate size and number of endometriotic lesions after medical treatment. Finally, our study lacked a third group without medical treatment after conservative surgical treatment.

The important aspect of this study is that it is the first to evaluate use of simvastatin to relieve endometriotic pains.

Further investigations without the limitations of the present study should provide more precise assessment of the effects of simvastatin on endometriotic lesions.

Conclusions
===========

GnRHa is one of the most accepted medical treatments of endometriosis, but the role of statins in endometriosis had been assessed only *in vitro* or in animal models. Our study assessed the effect of simvastatin on symptoms of endometriosis and found that it is comparable with Decapeptyl.

**Source of support:** Minimally Invasive Surgery Research Center, Rasool Akram Hospital, Tehran University of Medical Sciences (T.U.M.S), Tehran, Iran

###### 

Comparison of marital status in two patient groups.

                                          Drug     Total   
  ---------------- ------------- -------- -------- ------- ----
  Marital status   Single        Count    12       13      25
  Percent          40.0%         43.3%    41.7%            
  Married          Count         18       17       35      
  Percent          60.0%         56.7%    58.3%            
  Endometrioma     No or \<3cm   Count    12       5       17
  Percent          40.0%         16.7%    28.3%            
  ≥3 cm            Count         18       25       43      
  Percent          60.0%         83.3%    71.7%            
  Total                          Count    30       30      60
  Percent          100.0%        100.0%   100.0%           

###### 

Frequency of different reasons for laparoscopy in two groups.

  Different reasons                                 Drug     Total    
  ---------------------------------------- -------- -------- -------- ----
  Infertility                              Count    12       4        16
  Percent                                  40.0%    13.3%    26.7%    
  Dysmenorrhea                             Count    3        9        12
  Percent                                  10.0%    30.0%    20.0%    
  Dyspareunia                              Count    1        0        1
  Percent                                  3.3%     .0%      1.7%     
  Pelvic pain                              Count    3        4        7
  Percent                                  10.0%    13.3%    11.7%    
  Ovarian cyst                             Count    10       12       22
  Percent                                  33.3%    40.0%    36.7%    
  Infertility&ovarian cyst                 Count    0        1        1
  Percent                                  .0%      3.3%     1.7%     
  Infertility&ovarian cyst& dysmenorrhea   Count    1        0        1
  Percent                                  3.3%     .0%      1.7%     
  Total                                    Count    30       30       60
  Percent                                  100.0%   100.0%   100.0%   

###### 

Severity of endometriosis in two patient groups.

  Severity of endometriosis            Drug     Total    
  --------------------------- -------- -------- -------- ----
  Minimal+mild                Count    13       9        22
  Percent                     43.3%    30.0%    36.7%    
  Moderate                    Count    10       8        18
  Percent                     33.3%    26.7%    30.0%    
  Severe                      Count    7        13       20
  Percent                     23.3%    43.3%    33.3%    
  Total                       Count    30       30       60
  Percent                     100.0%   100.0%   100.0%   

###### 

comparison of age and severity of dyspareunia, dysmenorrhea and pelvic pain in two patient groups.

                                                                Drug          N       Mean    Std. deviation   P value
  ------------------------------------------------------------- ------------- ------- ------- ---------------- ---------
  Age                                                           Simvastatin   30      28.83   5.814            0.614
  GNRH                                                          30            29.77   5.643                    
  Dyspareunia before                                            Simvastatin   18      3.39    3.146            0.858
  GNRH                                                          17            3.59    3.318                    
  Dysmenorrhea before                                           Simvastatin   30      6.00    2.613            0.185
  GNRH                                                          30            6.63    3.211                    
  Pelvic pain before                                            Simvastatin   30      4.33    3.294            0.358
  GNRH                                                          30            5.07    3.107                    
  Dyspareunia after                                             Simvastatin   18      1.06    1.349            0.386
  GNRH                                                          17            1.59    1.661                    
  Dysmenorrhea after                                            Simvastatin   30      3.40    2.799            0.845
  GNRH                                                          30            3.17    2.052                    
  Pelvic pain after                                             Simvastatin   30      1.97    2.042            0.083
  GNRH                                                          30            2.83    2.001                    
  Dysmenorrhea(difference between before and after treatment)   Simvastatin   30      2.60    2.486            0.152
  GNRH                                                          30            3.47    2.129                    
  Pelvic pain (difference between before and after treatment)   Simvastatin   30      2.37    2.773            0.882
  GNRH                                                          30            2.23    1.654                    
  Dyspareunia (difference between before and after treatment)   Simvastatin   18      2.33    2.275            0.807
  GNRH                                                          17            2.00    1.936                    

###### 

Comparison of parameters before and after treatment in each group.

                                             Mean   N       Std. deviation   P value
  --------------------- -------------------- ------ ------- ---------------- ---------
  Simvastatin           Dyspareunia before   3.39   18      3.146            \<0.001
  Dyspareunia after     1.06                 18     1.349                    
  Dysmenorrhea before   6.00                 30     2.613   \<0.001          
  Dysmenorrhea after    3.40                 30     2.799                    
  Pelvic pain before    4.33                 30     3.294   \<0.001          
  Pelvic pain after     1.97                 30     2.042                    
  GNRH                  Dyspareunia before   3.59   17      3.318            0.001
  Dyspareunia after     1.59                 17     1.661                    
  Dysmenorrhea before   6.63                 30     3.211   \<0.001          
  Dysmenorrhea after    3.17                 30     2.052                    
  Pelvic pain before    5.07                 30     3.107   \<0.001          
  Pelvic pain after     2.83                 30     2.001                    
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